Medicamen Biotech Limited

NSE MEDICAMEQ.NS

Medicamen Biotech Limited Total Non-Current Liabilities for the year ending March 31, 2024: USD 361.02 K

Medicamen Biotech Limited Total Non-Current Liabilities is USD 361.02 K for the year ending March 31, 2024, a 17.30% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Medicamen Biotech Limited Total Non-Current Liabilities for the year ending March 31, 2023 was USD 307.79 K, a -64.23% change year over year.
Medicamen Biotech Limited Total Non-Current Liabilities for the year ending March 31, 2022 was USD 860.40 K, a -19.68% change year over year.
Medicamen Biotech Limited Total Non-Current Liabilities for the year ending March 31, 2021 was USD 1.07 M, a 125.31% change year over year.
Medicamen Biotech Limited Total Non-Current Liabilities for the year ending March 31, 2020 was USD 475.44 K, a 133.43% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NSE: MEDICAMEQ.NS

Medicamen Biotech Limited

CEO	Mr. Rajesh Madan B. Pharma
IPO Date	Oct. 27, 2021
Location	India
Headquarters	1506, Chiranjiv Tower
Employees	378
Sector	Health Care
Industries Pharmaceuticals

Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

Key trends

Past 5 years